✦ LIBER ✦

Implications of the new FDA/CDER immunotoxicology guidance for drugs

✍ Scribed by Kenneth L. Hastings

Book ID: 117798041
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 90 KB
Volume: 2
Category: Article
ISSN: 1567-5769
DOI: 10.1016/s1567-5769(02)00061-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk-Based Monitoring: Implications of t

Risk-Based Monitoring: Implications of the US FDA Guidance for Pharmaceutical Physicians

✍ Stoltz, Randall R. 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 137 KB

FDA'S policy statement for the developme

FDA'S policy statement for the development of new stereoisomeric drugs

📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 337 KB

The FDA's new procedures for the use of

The FDA's new procedures for the use of investigational drugs in treatment

✍ Young, F.E.; Norris, J.A.; Levitt, J.A.; Nightingale, S.L. 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Use of pain instruments as endpoints in

Use of pain instruments as endpoints in regulatory submissions: implications of the US FDA's new Patient Reported Outcomes (PRO) Guidance

✍ P. Black; A. Shields; K. Halling 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 33 KB

The “High Solubility” Definition of the

The “High Solubility” Definition of the Current FDA Guidance on Biopharmaceutical Classification System May Be Too Strict for Acidic Drugs

✍ Mehran Yazdanian; Katherine Briggs; Corinne Jankovsky; Amale Hawi 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 98 KB

Highly Variable Drugs: Observations from

Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug Applications

✍ Barbara M. Davit; Dale P. Conner; Beth Fabian-Fritsch; Sam H. Haidar; Xiaojian J 📂 Article 📅 2008 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 234 KB